Rising Cardiovascular Disease Incidence Sparks Surge In Angiotensin Receptor Blockers Market Emerges as a Core Driver of the Angiotensin Receptor Blockers (ARBs) Market in 2025

"Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Is the Expected CAGR for the Angiotensin Receptor Blockers (ARBs) Market Through 2025?
The market size of angiotensin receptor blockers (ARBs) has seen a consistent growth in the past years. The market is projected to expand from $8.51 billion in 2024 to $8.87 billion in 2025, with a compound annual growth rate (CAGR) of 4.1%. The growth during the previous years can be linked to factors such as the surge in hypertension cases, proven clinical efficacy, the increasing burden of cardiovascular diseases, renal protection benefits, clinical guidelines, the use of ARBs as the frontline treatment, and their cost-effectiveness.

What's the Projected Size of the Global Angiotensin Receptor Blockers (ARBs) Market by 2029?
The market size of angiotensin receptor blockers (ARBs) is anticipated to undergo consistent growth over the next several years, eventually reaching $10.76 billion in 2029 with a compound annual growth rate (CAGR) of 5.0%. This upward trend during the forecast period can be ascribed to the adoption of precision medicine strategies, emphasis on combination therapies, global market expansion, the application of biomarker-oriented treatment plans, government-led initiatives, and the heightened understanding of hypertension. The forecast period is also predicted to experience trends such as the integration of telemedicine, increased research and development investments, the rise of generic competition and patent expiration sagas, the incorporation of digital health strategies to ensure medication compliance, and the escalating competition from biosimilars.

View the full report here:
https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Top Growth Drivers in the Angiotensin Receptor Blockers (ARBs) Industry: What's Accelerating the Market?
The rise in cardiovascular disease cases is anticipated to boost the angiotensin receptor blockers market's expansion. Cardiovascular disease (CVD) pertains to any disorder impacting the heart or blood vessels, often linked with atherosclerosis, a condition characterized by fat deposits in arteries and a heightened threat of blood clots. Angiotensin receptor blockers are effective in reducing blood pressure and enhancing the ability of the heart to pump blood as they aid in the relaxation of veins and arteries, thereby reducing the chances of cardiovascular disease. For example, the American College of Cardiology, a professional medical organization in the US, predicted in August 2022 that cardiovascular risk factors and disease rates in the United States will noticeably increase by the year 2060. Thus, the escalating prevalence of cardiovascular diseases is fueling the growth of the angiotensin receptor blockers market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

What Trends Will Shape the Angiotensin Receptor Blockers (ARBs) Market Through 2029 and Beyond?
Prominent entities in the angiotensin receptor blocker industry are innovating with products like angiotensin receptor neprilysin inhibitors to offer improved treatments and enhance patients' outcomes dealing with cardiovascular issues. Medications such as angiotensin receptor neprilysin inhibitors (ARNIs) are extensively used for the treatment of heart failure. For example, Glenmark Pharmaceuticals, a pharmaceutical enterprise based in India, introduced sacubitril + valsartan tablets in January 2023. These tablets cater specially to heart failure treatment, focusing particularly on heart failure with reduced ejection fraction (HFrEF). The said combination is categorized under ARNI (angiotensin receptor neprilysin inhibitors)-type medications. Sacubitril aids the natriuretic peptide (NP) system to relieve fluid overload and support blood vessel expansion, whereas valsartan blocks the renin-angiotensin system (RAS), reducing blood pressure and the heart's effort. Collectively, they effectively mitigate symptoms of heart failure, lower cardiovascular mortality risk, and minimize the likelihood of heart failure-based hospitalizations. These are sold under the brand name Sacu V.

What Are the Main Segments in the Angiotensin Receptor Blockers (ARBs) Market?
The angiotensin receptor blockers (ARBs) market covered in this report is segmented -

1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan
2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications
3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Subsegments:
1) By Valsartan: Tablets, Capsules, Injectable Forms
2) By Telmisartan: Tablets, Capsules
3) By Losartan: Tablets, Oral Solution
4) By Irbesartan: Tablets, Oral Solution
5) By Azilsartan: Tablets
6) By Olmesartan: Tablets, Oral Suspension

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp

Which Top Companies are Driving Growth in the Angiotensin Receptor Blockers (ARBs) Market?
Major companies operating in the angiotensin receptor blockers (ARBs) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy's Laboratories Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma

Which Regions Will Dominate the Angiotensin Receptor Blockers (ARBs) Market Through 2029?
North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8943

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Contact Us:
The Business Research Company
Europe: +44 7882 955267
Asia: +91 88972 63534
Americas: +1 310-496-7795
Email: info@tbrc.info
Follow Us On:
•LinkedIn: https://in.linkedin.com/company/the-business-research-company
•Twitter: https://twitter.com/tbrc_info
•YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.